Latest News and Press Releases

Jnana Therapeutics presents new positive data at SSIEM 2024 from Phase 1/2 study of JNT-517 in individuals with phenylketonuria (PKU).

Otsuka Pharmaceutical to acquire Jnana Therapeutics Inc.

Jnana CEO Joanne Kotz will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 at 2:05 p.m. ET.

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for...

Jnana Therapeutics announces positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with PKU.

Jnana Therapeutics CEO Joanne Kotz, PhD, will present at the J.P. Morgan Healthcare Conference on Monday, January 8, at 5:30pm PT.

Jnana Therapeutics CEO Joanne Kotz will participate in a fireside chat on Dec. 13 at the RBC Capital Markets Healthcare Private Company Conference.

Jnana Therapeutics CEO Joanne Kotz, Ph.D., will present a corporate overview at the Piper Sandler 35th Annual Healthcare Conference.

BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets,...

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets,...